NYSE:WST
WEST PHARMACEUTICAL SERVICES INC
A leading global provider of single-use bioprocessing systems and packaging solutions driving growth in the pharmaceutical supply chain.
Key Metrics
Investment Thesis
Bull Case
Investors should consider the secular tailwinds from biologics market expansion which drives sustained demand for flexible single-use processing solutions. The company's dominant market position allows it to maintain pricing power and high gross margins of approximately 36%. Robust balance sheet with $791.3M in cash provides ample runway for strategic acquisitions and R&D without needing external financing.
Bear Case
Valuation may be stretched given the recent stagnation in revenue growth between 2024 and 2025, potentially limiting upside potential near-term. High levels of goodwill at $109.9M create intangible asset risk if future acquisitions underperform or integration costs escalate. Dependence on a few large pharmaceutical customers creates vulnerability to contract losses or pricing negotiations that could impact cash flows.
About WEST PHARMACEUTICAL SERVICES INC
West Pharmaceutical Services Inc. designs, manufactures, and supplies single-use bioprocessing systems and packaging solutions for the pharmaceutical, biotechnology, and medical device industries globally. The company serves a diverse customer base including major pharmaceutical companies, biotech firms, and contract manufacturing organizations with its proprietary single-use technologies. Revenue grew to $3.07B in 2025, reflecting strong demand for flexible manufacturing solutions in complex biologics production.
Analysis
Management Discussion
The company delivered $493.7M in net profit for 2025, maintaining profitability despite a slight revenue plateau compared to recent years. Strong cash flow from operations of $754.8M highlights robust liquidity and efficient working capital management with accounts receivable at $574.4M. Capital expenditures of $285.9M indicate continued investment in manufacturing capacity and technology development to support long-term growth.
Industry Overview
The global bioprocessing equipment and packaging market is experiencing significant growth driven by the shift from traditional stainless steel manufacturing to flexible single-use technologies. This transition is accelerating as pharma companies seek faster time-to-market for novel therapies and smaller batch sizes typical of biologic drugs. Regulatory bodies increasingly scrutinize supply chain security, favoring diversified suppliers like West who offer comprehensive end-to-end solutions.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.89B | $2.95B | $2.89B | $3.07B |
| Cost of Revenue | $1.75B | $1.82B | $1.89B | $1.97B |
| Gross Profit | $1.14B | $1.13B | $998.5M | $1.10B |
| Operating Expenses | $402.2M | $453.2M | $428.6M | $519.1M |
| Operating Income | $734.0M | $676.0M | $569.9M | $584.9M |
| R&D | $58.5M | $68.4M | $69.1M | $74.3M |
| G&A | $316.9M | $353.4M | $338.5M | $393.6M |
| Stock-Based Comp | $23.7M | $23.3M | $18.7M | $23.8M |
| D&A | $120.6M | $137.3M | $155.4M | $171.4M |
| Depreciation | $116.9M | $133.7M | $151.8M | $168.6M |
| Amortization | $3.7M | $3.6M | $3.6M | $2.8M |
| Other OpEx | $26.8M | $31.4M | $21.0M | $51.2M |
| Non-Operating Income | $-54.1M | $22.0M | $15.6M | $16.0M |
| Interest Expense | $7.9M | $9.0M | — | — |
| Pre-Tax Income | $679.9M | $698.0M | $585.5M | $600.9M |
| Income Tax | $114.7M | $122.3M | $107.5M | $121.6M |
| Continuing Ops | $565.2M | $575.7M | $478.0M | $479.3M |
| Discontinued Ops | $20.7M | $17.7M | $14.7M | $14.4M |
| Net Income | $585.9M | $593.4M | $492.7M | $493.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $585.9M | $593.4M | $492.7M | $493.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.92B | $1.94B | $1.54B | $1.98B |
| Cash & Equivalents | $894.3M | $853.9M | $484.6M | $791.3M |
| Accounts Receivable | $507.4M | $512.0M | $552.5M | $574.4M |
| Inventory | $414.8M | $434.7M | $377.0M | $443.9M |
| Other Current Assets | $103.0M | $135.8M | $124.0M | $168.6M |
| Long-Term Assets | $1.70B | $1.89B | $2.11B | $2.29B |
| PP&E (Net) | $1.16B | $1.41B | $1.58B | $1.73B |
| Intangibles | $18.4M | $15.1M | $10.8M | $7.7M |
| Goodwill | $107.3M | $108.5M | $106.0M | $109.9M |
| Operating Leases | $104.4M | $99.2M | $104.5M | $117.0M |
| Other LT Assets | $111.9M | $53.8M | $107.5M | $122.5M |
| Total Assets | $3.62B | $3.83B | $3.64B | $4.27B |
| Current Liabilities | $519.0M | $671.8M | $550.4M | $654.9M |
| Accounts Payable | $215.4M | $242.4M | $239.3M | $253.7M |
| Current Debt | $2.2M | $134.0M | $0 | $0 |
| Current Leases | $16.0M | $17.7M | $17.9M | $22.7M |
| Taxes Payable | $24.8M | $16.6M | $31.5M | $28.1M |
| Other Current Liab | $246.5M | $246.3M | $246.5M | $334.6M |
| Long-Term Liabilities | $412.9M | $276.7M | $410.7M | $439.1M |
| Long-Term Debt | $206.7M | $72.8M | $202.6M | $202.8M |
| LT Operating Leases | $93.0M | $84.5M | $81.8M | $95.6M |
| Other LT Liab | $113.2M | $119.4M | $126.3M | $140.7M |
| Total Liabilities | $931.9M | $948.5M | $961.1M | $1.09B |
| Shareholders' Equity | $2.68B | $2.88B | $2.68B | $3.18B |
| Paid-In Capital | $232.2M | $120.2M | $22.1M | $0 |
| Retained Earnings | $2.99B | $3.52B | $3.96B | $4.37B |
| AOCI | $-183.0M | $-143.8M | $-258.1M | $-105.5M |
| Treasury Stock | $370.9M | — | — | — |
| Total L&E | $3.62B | $3.83B | $3.64B | $4.27B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $585.9M | $593.4M | $492.7M | $493.7M |
| Non-Cash Adjustments | $132.2M | $153.9M | $156.7M | $316.0M |
| Working Capital Changes | $5.9M | $29.2M | $4.0M | $-54.9M |
| Cash from Operations | $724.0M | $776.5M | $653.4M | $754.8M |
| Capital Expenditures | $284.6M | $362.0M | $377.0M | $285.9M |
| Cash from Investing | $-288.2M | $-368.7M | $-378.7M | $-285.9M |
| Debt Repayments | $1.2M | — | $169.0M | $0 |
| Share Buybacks | $202.8M | $438.3M | $560.9M | $134.0M |
| Dividends Paid | $54.1M | $57.0M | $59.1M | $61.2M |
| Cash from Financing | $-293.6M | $-459.6M | $-622.6M | $-185.1M |
| FX Effect | $-10.5M | $11.4M | $-21.4M | $22.9M |
| Net Change in Cash | $131.7M | $-40.4M | $-369.3M | $306.7M |
| Beginning Cash | $762.6M | $894.3M | $853.9M | $484.6M |
| Ending Cash | $894.3M | $853.9M | $484.6M | $791.3M |
Frequently Asked Questions
How does WEST PHARMACEUTICAL SERVICES INC make money?
Primary revenue streams include single-use bioprocessing systems for upstream/downstream processing, specialized packaging solutions for drug delivery devices, and related consumables that enable flexible and hygienic manufacturing environments.
What are the main risks for WST?
Regulatory changes affecting single-use system approvals or environmental policies regarding plastic usage could impact adoption rates. Concentration risk within the pharmaceutical sector where a downturn in drug development spending directly affects order books. Supply chain disruptions for raw materials such as polymers could marginally compress operating margins. Currency fluctuations may erode reported earnings given the company's significant international operations.
What is WST's competitive advantage?
Proprietary single-use technology platforms reduce capital expenditure for customers while enabling rapid scale-up of biologics production. Strong global distribution network and established relationships with top-tier pharmaceutical clients provide high switching costs. Continuous innovation in material science allows the company to capture value from emerging therapies like gene and cell therapy.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.